Suche
Mein Konto
UC researchers receive NIH grant to study how alcohol and fentanyl affect HIV drugs
The United States has set a goal of reducing the number of new HIV infections by 75% by 2025 and by at least 90% by 2030, reflecting the United Nations initiative to end the AIDS epidemic as a global health threat by 2030. Part of achieving these goals is ensuring the safety and effectiveness of HIV medications in various settings, and researchers at the University of Cincinnati recently received a $3.5 million National Institutes of Health grant that will study how current medications are affected by alcohol consumption alone in combination with fentanyl. Study background Bingfang Yan, …
UC researchers receive NIH grant to study how alcohol and fentanyl affect HIV drugs
The United States has set a goal of reducing the number of new HIV infections by 75% by 2025 and by at least 90% by 2030, reflecting the United Nations initiative to end the AIDS epidemic as a global health threat by 2030.
Part of achieving these goals is ensuring the safety and effectiveness of HIV medications in various settings, and researchers at the University of Cincinnati recently received a $3.5 million National Institutes of Health grant that will study how current medications are affected by alcohol consumption alone in combination with fentanyl.
Study background
Bingfang Yan, PhD, DVM, contact principal investigator of the research, said there is no clear data showing how alcohol with or without fentanyl affects HIV medications, including pre-exposure prophylaxis (PrEP) medications, which are taken to reduce the likelihood of HIV infection.
It is widely accepted that unhealthy alcohol consumption has been linked to poor adherence to PrEP and medication skipping. However, it is not clear whether and how alcohol with or without fentanyl directly affects the effectiveness and safety of HIV medications.”
Bingfang Yan, professor and associate dean for research and innovation at UC's James L. Winkle College of Pharmacy
Immunology e-book
Compilation of the top interviews, articles and news from the last year. Download a free copy
A research team with diverse backgrounds was formed to learn more, including co-principal investigators Jason Blackard, PhD, professor of internal medicine at the UC College of Medicine, and Jennifer Brown, PhD, associate professor at Purdue University and former faculty member at the UC College of Arts and Sciences. Yan brings research experience in drug metabolism, Blackard's lab studies viral interactions, and Brown has a research focus on alcohol and substance use.
“This is a collaborative effort and represents an excellent example of bringing complementary expertise together to solve important health problems,” Yan said.
Study details
Yan said this project will analyze cell cultures as well as blood, hair, urine and white blood cell samples from patients participating in the study.
The first objective of the study is to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations who consume alcohol with or without fentanyl compared to those who do not.
“Altered metabolite signatures and pharmacological biomarkers suggest that alcohol consumption alone or in combination with fentanyl would make PrEP less effective,” Yan said.
The second aim is similar and compares the effectiveness and safety and adherence of HIV therapy in HIV-positive populations who use alcohol alone or in combination with fentanyl versus those who do not.
“Goal 1 focuses on prevention and Goal 2 focuses on treatment,” Yan said. “It’s very comprehensive, so the information gained will be really meaningful.”
Source:
.